Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma

British Journal of Cancer

Volumn 109, Issue 1, 2013, Pages 8-13

  Sherrill, B ^a   Wang, J ^a   Kotapati, S ^b   Chin, K ^b  

^a RTI HEALTH SOLUTIONS   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DACARBAZINE; IPILIMUMAB; PLACEBO;

ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; FOLLOW UP; HEALTH STATUS; HUMAN; IN-TRANSIT METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PERSONAL EXPERIENCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SATELLITE METASTASIS; SURVIVAL TIME; TOXICITY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, ALKYLATING; DACARBAZINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; HUMANS; MELANOMA; NEOPLASM STAGING; SURVIVAL ANALYSIS;

EID: 84880307128     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.298     Document Type: Article

References (23)

1. Agarwala SS (2009) Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther 9: 587-595.
2. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Restifo NP, Haworth LR, Levy C, Mavroukakis SA, Nichol G, Yellin MJ, Rosenberg SA (2005) Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23(25): 6043-6053.
3. Batty AJ, Fisher D, Winn B, Wang Q, Tolley K, Rowen D (2011) Estimating quality of life in advanced melanoma; a comparison of standard gamble, SF-36 mapped, and EORTC QLQ-C30 mapped utilities. Value Health 14: A461-A462.
4. Beusterien KM, Szabo SM, Kotapati S, Mukherjee J, Hoos A, Hersey P, Middleton MR, Levy AR (2009) Societal preference values for advanced melanoma health states in the United Kingdom and Australia. Br J Cancer 101: 387-389.
5. Cole BF, Gelber RD, Anderson KM. International Breast Cancer Study Group (1994) Parametric approaches to quality-adjusted survival analysis. Biometrics 50: 621-631.
6. Cole BF, Gelber RD, Kirkwood JM, Goldhirsch A, Barylak E, Borden E (1996) Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 14: 2666-2673.
7. Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Allen TE, Levy CL, Yellin M, Nichol G, White DE, Steinberg SM, Rosenberg SA (2007) Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 13: 6681-6688.
8. Gao F, Wee J, Wong HB, Machin D (2010) Quality-of-life-adjusted survival analysis of concurrent chemo radiotherapy for locally advanced (nonmetastatic) nasopharyngeal cancer. Int J Radiat Oncol Biol Phys 78: 454-460.
9. Glasziou PP, Simes RJ, Gelber RD (1990) Quality adjusted survival analysis. Stat Med 9: 1259-1276.
10. Goldhirsch A, Gelber RD, Simes RJ, Glasziou P, Coates AS (1989) Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. J Clin Oncol 7: 36-44.
11. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723.
12. Jang RW, Le Maître A, Ding K, Winton T, Bezjak A, Seymour L, Shepherd FA, Leighl NB (2009) Quality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: an analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial. J Clin Oncol 27: 4268-4273.
13. Julia F, Thomas L, Dumontet C, Dalle S (2010) Targeted therapies in metastatic melanoma: toward a clinical breakthrough? Anticancer Agents Med Chem 10: 661-665.
14. Kilbridge KL, Cole BF, Kirkwood JM, Haluska FG, Atkins MA, Ruckdeschel JC, Sock DE, Nease Jr RF, Weeks JC (2002) Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data. J Clin Oncol 20: 1311-1318.
15. Kotapati S, Francis S, Sherrill B (2011) Health related quality of life (HRQL) of patients receiving ipilimumab with dacarbazine as first-line treatment for unresectable stage III/IV (III/IV) melanoma. Poster presented at the 8th International Congress of The Society for Melanoma Research, Tampa, FL, USA.
16. Marcus R, Aultman R, Jost F (2010) A quality-adjusted survival analysis (Q-TWiST) of rituximab plus CVP vs CVP alone in first-line treatment of advanced follicular non-Hodgkin's lymphoma. Br J Cancer 102: 19-22.
17. Patil S, Figlin RA, Hutson TE, Michaelson MD, Negrier S, Kim ST, Huang X, Motzer RJ (2012) Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-a. Br J Cancer 106: 1587-1590.
18. Robert C, Thomas L, Bondarenko I, O'Day S, M D JW, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller Jr WH, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364: 2517-2526.
19. Sherrill B, Sherif B, Amonkar MM, Maltzman J, O'Rourke L, Johnston S (2011) Quality-adjusted survival analysis of first-line treatment of hormone-receptor-positive HER2metastatic breast cancer with letrozole alone or in combination with lapatinib. Curr Med Res Opin 27(12): 2245-2252.
20. Sloan JA, Sargent DJ, Lindman J, Allmer C, Vargas-Chanes D, Creagan ET, Bonner JA, O'Connell MJ, Dalton RJ, Rowland KM, Brooks BJ, Laurie JA (2002) A new graphic for quality adjusted life years (Q-TWiST) survival analysis: the Q-TWiST plot. Qual Life Res 11: 37-45.
21. Wang J, Zhao Z, Barber B, Sherrill B, Peeters M, Wiezorek J (2011) A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer. Br J Cancer 104(12): 1848-1853.
22. Weber J, Kahler K, Hauschild A (2012) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30(21): 2691-2697.
23. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15: 7412-7420.